SPOTLIGHT: Merck seeks trial delay

Merck has asked a judge to delay a trial over Vioxx scheduled to begin next week, saying that recent publicity would make it impossible to obtain a fair trial on the issue. Story

Suggested Articles

The FDA rejected the new drug application for golodirsen, the follow-up to Exondys 51, Sarepta’s first treatment for Duchenne muscular dystrophy.

Levi Garraway is set to take up one of the biggest hot seats in biopharma when he becomes the next chief medical officer at Roche.

Vanda Pharmaceuticals received a Complete Response Letter from the FDA taking issue with a small study testing Hetlioz in jet lag disorder.